Interaction between TNF inhibitors and serum IL-17 levels and susceptibility to rheumatoid arthritis
DOI:
https://doi.org/10.12923/Keywords:
IL-17, TNF inhibitors, rheumatoid arthritis, susceptibilityAbstract
This study aimed to assess the central role of the immunological marker interleukin-17 (IL-17) and to investigate the interaction between tumor necrosis factor (TNF) inhibitors and serum IL-17 levels in relation to susceptibility in patients with rheumatoid arthritis (RA). Serum samples were collected from three groups: patients with RA receiving TNF inhibitor therapy, patients with newly diagnosed (early) RA, and healthy controls. Serum IL-17 levels were measured using enzyme-linked immunosorbent assay (ELISA). Serum IL-17 concentrations were significantly higher in RA patients treated with TNF inhibitors compared with the other groups (p < 0.001). Based on the present findings, increased serum IL-17 levels in RA patients undergoing TNF inhibitor therapy may indicate a better response to anti-TNF treatment.
References
1. Cush JJ. Rheumatoid arthritis: early diagnosis and treatment. Rheum Dis Clin North Am. 2022;48(2):537–547.
2. Deane KD. Preclinical rheumatoid arthritis and rheumatoid arthritis prevention. Curr Rheumatol Rep. 2018;20:1–7.
3. Gerriets V, Goyal A, Khaddour K. Tumor necrosis factor inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
4. Scirè CA, et al. Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis. 2014;73(9):1677–1682.
5. Berry SPD-G, et al. The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases. Int Immunopharmacol. 2022;102:108402.
6. van der Woude D, van der Helm-van Mil AHM. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2018;32(2):174–187.
7. Khadim RM, Al-Fartusie FS. Evaluation of liver function and lipid profiles in Iraqi patients with rheumatoid arthritis. J Phys Conf Ser. 2021;1853(1):012040.
8. Sadeq KH, Ahmed AA, Mohammed HA. The effect of tumor necrosis factor alpha polymorphism on response to biological treatment for rheumatoid arthritis patients. Iraqi J Med Sci. 2017;15(3):220–226.
9. Al-Saffar EA, Al-Saadi BQ. Association of IRAK1 gene polymorphism and some immunological markers with the risk of rheumatoid arthritis in Iraqi patients. Iraqi J Biotechnol. 2022;21(2): 46–60.
10. Ahmed AH. Relationship between interleukin-10, interleukin-6, anti-cyclic citrullinated peptide antibodies, C-reactive protein, and rheumatoid factor in patients with rheumatoid arthritis. Al-Qadisiyah Med J. 2015;11(20):190–196.
11. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017;31(1):3–18.
12. Beyazal MS, Devrimsel G, Cüre MC, et al. Serum levels of IL-17, IL-6, TNF-α and disease activity in patients with rheumatoid arthritis. Aktuelle Rheumatol. 2017;42(4):323–328.
13. Mrabet D, Laadhar L, Sahli H, et al. Synovial fluid and serum levels of IL-17, IL-23, and CCL20 in rheumatoid arthritis and psoriatic arthritis: a Tunisian cross-sectional study. Rheumatol Int. 2013;33:265–266.
14. Zhang L, Li YG, Li YH, et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One. 2012;7:e31000.
15. Millier MJ, Fanning NC, Frampton C, et al. Plasma interleukin-23 and circulating IL-17A+IFNγ+ ex-Th17 cells predict opposing outcomes of anti-TNF therapy in rheumatoid arthritis. Arthritis Res Ther. 2022;24:57.
16. Sikorska D, Rutkowski R, Łuczak J, Samborski W, Witowski J. No effect of anti-TNF-α treatment on serum IL-17 in patients with rheumatoid arthritis. Cent Eur J Immunol. 2018;43(3):270–275.
17. Chen DY, et al. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Res Ther. 2011;13:R126.
18. Fakher YS, Shaheed OM. Interleukin-22 as a biomarker for rheumatoid arthritis in Iraqi population. J Pharm Negat Results. 2022;13(2):209–212.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Orass Madhi Shaheed, Maryam Yaseen Shaker, Mohauman Mohammed AlRufaie (Autor)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
